A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Upadacitinib in Pediatric Participants With Severe Atopic Dermatitis
Public ClinicalTrials.gov record NCT03646604. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-label Multiple Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Upadacitinib in Pediatric Subjects With Severe Atopic Dermatitis
Study identification
- NCT ID
- NCT03646604
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- AbbVie
- Industry
- Enrollment
- 35 participants
Conditions and interventions
Conditions
Interventions
- Upadacitinib (ABT-494) Drug
Drug
Eligibility (public fields only)
- Age range
- 2 Years to 12 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 30, 2019
- Primary completion
- Aug 28, 2024
- Completion
- Aug 28, 2024
- Last update posted
- Feb 9, 2025
2019 – 2024
United States locations
- U.S. sites
- 15
- U.S. states
- 12
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Beach Pediatrics /ID# 207834 | Huntington Beach | California | 92647-6818 | — |
| Children's Hospital Los Angeles /ID# 206042 | Los Angeles | California | 90027 | — |
| Pediatric Skin Research, LLC /ID# 213468 | Coral Gables | Florida | 33146-1837 | — |
| Rybear, Inc /ID# 231801 | Fort Lauderdale | Florida | 33316-1952 | — |
| IACT Health-Columbus /ID# 216370 | Columbus | Georgia | 31904-8946 | — |
| Northwestern University Feinberg School of Medicine /ID# 206224 | Chicago | Illinois | 60611-2927 | — |
| Dawes Fretzin, LLC /ID# 214958 | Indianapolis | Indiana | 46256 | — |
| Duplicate_Washington University of St. Louis /ID# 206972 | St Louis | Missouri | 63141-6399 | — |
| University of New Mexico School of Medicine /ID# 206757 | Albuquerque | New Mexico | 87131-0001 | — |
| Cincinnati Children's Hospital /ID# 207071 | Cincinnati | Ohio | 45229 | — |
| Oregon Medical Research Center /ID# 206226 | Portland | Oregon | 97239 | — |
| Penn State University and Milton S. Hershey Medical Center /ID# 207096 | Hershey | Pennsylvania | 17033-2360 | — |
| Paddington Testing Co., Inc. /ID# 207079 | Philadelphia | Pennsylvania | 19103 | — |
| Arlington Research Center, Inc /ID# 222901 | Arlington | Texas | 76011 | — |
| West Virginia University Hospitals /ID# 206792 | Morgantown | West Virginia | 26506 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03646604, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 9, 2025 · Synced May 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03646604 live on ClinicalTrials.gov.